TheraCarb Inc.

November 20, 2006 17:36 ET

TheraCarb Wins Award

CALGARY, ALBERTA--(CCNMatthews - Nov. 20, 2006) - TheraCarb is pleased to announce that it was awarded the Forum Favorite Award for Best Company - Biotechnology at the Canadian Financing Forum held on November 13th and 14th in Vancouver.

The 10th Annual Financing Forum, featured presentations from the best and most
promising private technology companies in Canada, with 35 technology companies
competing for attention from over 70 top tier investors from across Canada and the United States.

"We were honoured to be selected to present at the Financing Forum and excited to have won this award", said Dr. Mary Earle, President and CEO of TheraCarb. "To be selected the Favorite Award for Best Company - Biotechnology by premier North American investors confirms our commitment and dedication to making TheraCarb successful."

"TheraCarb impressed the attendees at the Canadian Financing Forum winning the
Forum Favorite award for Biotechnology. Their vaccine and drug development programs target large markets and the company has made significant progress in 2006." said Dave Thomas, General Manager of the Canadian Financing Forum. "They are establishing themselves as one of the promising early stage Biotech companies in Western Canada."

The Canadian Financing Forum is the leading showcase for venture capital investment in Canadian companies focused on information technology, biotechnology and cleantech & advanced technology. It was founded in 1995 as a joint venture between Macdonald & Associates and, the leading Web gateway to news and information concerning the Canadian IT industry.

About TheraCarb

TheraCarb Inc. is a Calgary-based biotechnology company that is commercializing
synthetic carbohydrate vaccines and therapeutics for the prevention and treatment of two disease states; infection from Candida albicans, the fungus that causes yeast infections (thrush) and diseases caused by amyloid plaques, specifically Alzeimer's disease. TheraCarb is currently in the process of raising its first venture capital round of financing.

Contact Information